Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

medicinsketidsskrifter.dk

Factuality

Ownership

MEDICAL JOURNAL Significant announcement after phase III results: Fenebrutinib may become the best MS drug The BTK inhibitor fenebrutinib has apparently performed so significantly against both relapsing and primary progressive sclerosis in the first phase III studies that the pharmaceutical company Roche now estimates that fenebrutinib may become the “best-in-disease medicine.” “It is an exciting time for patients with MS and researchers in the …